Latest News

EUSA Pharma Announces Appointment of Carsten Thiel as New Chief Executive Officer

30/03/2021

Read More …

SYLVANT® (siltuximab) Recommended by the National Comprehensive Cancer Network® (NCCN®) as the Preferred Treatment Option for Patients with Idiopathic Multicentric…

25/02/2021

Read More …

EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for SYLVANT® (Siltuximab for Injection) in China…

25/01/2021

Read More …
All News